If you have been reading about reverse-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-02. Numbers and descriptions here follow the published literature rather than marketing material.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilized powder form |
| Solubility class | Freely soluble in water | Also dissolves in polar organic solvents |
| Typical storage temperature | Minus 20 degrees Celsius or lower | Desiccated and protected from light |
| Typical analytical method | Reversed-phase HPLC with UV detection | Purity reported by area normalization |
| Common synonyms | PT-141; bremelanotide | Research code and assigned generic name |
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
In 1917–18, two groups of scientists, Lise Meitner in collaboration with Otto Hahn of Germany and Frederick Soddy and John Cranston of Great Britain, independently discovered another isotope, 231Pa, having a much longer half-life of 32,760 years. Meitner changed the name "brevium" to protactinium as the new element was part of the decay chain of uranium-235 as the parent of actinium (from the Greek: πρῶτος prôtos, meaning "first, before"). The IUPAC confirmed this naming in 1949. The discovery of protactinium completed one of the last gaps in early versions of the periodic table, and brought fame to the involved scientists. Aristid von Grosse produced 2 milligrams of Pa2O5 in 1927, and in 1934 first isolated elemental protactinium from 0.1 milligrams of Pa2O5. He used two different procedures: in the first, protactinium oxide was irradiated by 35 keV electrons in vacuum. In the other, called the van Arkel–de Boer process, the oxide was chemically converted to a halide (chloride, bromide or iodide) and then reduced in a vacuum with an electrically heated metallic filament:
At higher doses, it can induce psychosis, rhabdomyolysis, and cerebral hemorrhage. Methamphetamine is known to have a high potential for abuse and addiction. Recreational use of methamphetamine may result in psychosis or lead to post-acute-withdrawal syndrome, a withdrawal syndrome that can persist for months beyond the typical withdrawal period. Unlike amphetamine and cocaine, methamphetamine is neurotoxic to humans, damaging both dopamine and serotonin neurons in the central nervous system (CNS). Unlike the long-term use of amphetamine in prescription doses, which may improve certain brain regions in individuals with ADHD, there is evidence that methamphetamine causes brain damage from long-term use in humans; this damage includes adverse changes in brain structure and function, such as reductions in gray matter volume in several brain regions and adverse changes in markers of metabolic integrity.
=== BLOSUM === BLOSUM80: more related proteins BLOSUM62: midrange BLOSUM45: distantly related proteins The BLOSUM62 matrix with the amino acids in the table grouped according to the chemistry of the side chain, as in (a). Each value in the matrix is calculated by dividing the frequency of occurrence of the amino acid pair in the BLOCKS database, clustered at the 62% level, divided by the probability that the same two amino acids might align by chance. The ratio is then converted to a logarithm and expressed as a log odds score, as for PAM. BLOSUM matrices are usually scaled in half-bit units. A score of zero indicates that the frequency with which a given two amino acids were found aligned in the database was as expected by chance, while a positive score indicates that the alignment was found more often than by chance, and negative score indicates that the alignment was found less often than by chance.
Dinuzulu made a pact with the Boers of his own, promising them land in return for their aid. The Boers were led by Louis Botha. Dinuzulu and the Boers defeated Zibhebhu in 1884. They were granted about half of Zululand individually as farms, and formed the independent Republic of Vryheid. This alarmed the British who wanted to prevent the Boers access to a harbour. The British then annexed Zululand in 1887. Dinuzulu became involved in later conflicts with rivals. In 1906 Dinuzulu was accused of being behind the Bambatha Rebellion. He was arrested and put on trial by the British for "high treason and public violence". In 1909, he was sentenced to ten years' imprisonment on St Helena island. When the Union of South Africa was formed, Louis Botha became its first prime minister, and he arranged for his old ally Dinuzulu to return to South Africa and live in exile on a farm in the Transvaal, where he died in 1913. Dinuzulu's son Solomon kaDinuzulu was never recognised by South African authorities as the Zulu king, only as a local chief, but he was increasingly regarded as king by chiefs, by political intellectuals such as John Langalibalele Dube and by ordinary Zulu people. In 1923, Solomon founded the organisation Inkatha YaKwaZulu to promote his royal claims, which became moribund and then was revived in the 1970s by Mangosuthu Buthelezi, chief minister of the KwaZulu bantustan.
Tillman Gerngross (born November 15, 1963) is an Austro-American scientist. He is a professor of bioengineering at the Thayer School of Engineering at Dartmouth College, and an adjunct professor in the departments of biology and chemistry at Dartmouth. Gerngross has been an active inventor and to date his work has resulted in the founding of multiple companies (GlycoFi, Inc., Adimab LLC, Arsanis, Inc., Alector [Nasdaq:ALEC], Avitide, Inc., Amagma, Inc., Ankyra, and Adagio [Nasdaq:ADGI]) and over a dozen U.S. and international patents. Gerngross was elected a member of the National Academy of Engineering in 2017.
Sources: en.wikipedia.org
=== Dermal filler === In 2006, the US Food and Drug Administration approved an injectable dermal filler form of calcium hydroxyapatite (Radiesse) for the correction of moderate-to-severe facial folds, such as nasolabial folds, and for the restoration of volume in cases of HIV-associated facial lipoatrophy. The formulation typically consists of synthetic, smooth calcium hydroxyapatite microspheres (20–45 μm in diameter) suspended in a carboxymethylcellulose carrier gel. Upon injection in the skin, the gel provides immediate mechanical volumization, while the microspheres function as a scaffold for the endogenous production of collagen, elastin, and proteoglycans. This process is reported to lead to increases in skin thickness and structural elasticity. Clinical applications include jawline augmentation, hand rejuvenation, and the treatment of midface volume loss. Calcium hydroxyapatite is biodegradable, with the microspheres eventually undergoing macrophage-mediated phagocytosis and metabolic clearance over a period of approximately 12 to 30 months.
Another difference between the older ACE inhibitors and RXP 407 is the molecular size of the compound. The older ACE inhibitors had mostly been interacting with S1’, S2’ and S1 subsites but RXP 407 interacts in addition with the S2 subsite. This also is important for the selectivity of the inhibitor since the aspartic side chain and N-acetyl group are located in the P2 position.
Moreover, if we move in the direction of making machines which learn and whose behavior is modified by experience, we must face the fact that every degree of independence we give the machine is a degree of possible defiance of our wishes. In 1988, Blay Whitby published a book outlining the need for AI to be developed along ethical and socially responsible lines. From 2008 to 2009, the Association for the Advancement of Artificial Intelligence (AAAI) commissioned a study to explore and address potential long-term societal influences of AI research and development. The panel was generally skeptical of the radical views expressed by science-fiction authors but agreed that "additional research would be valuable on methods for understanding and verifying the range of behaviors of complex computational systems to minimize unexpected outcomes". In 2011, Roman Yampolskiy introduced the term "AI safety engineering" at the Philosophy and Theory of Artificial Intelligence conference, listing prior failures of AI systems and arguing that "the frequency and seriousness of such events will steadily increase as AIs become more capable". In 2014, philosopher Nick Bostrom published the book Superintelligence: Paths, Dangers, Strategies. He has the opinion that the rise of AGI has the potential to create various societal issues, ranging from the displacement of the workforce by AI, manipulation of political and military structures, to even the possibility of human extinction.
== Medical uses == Probenecid is primarily used to treat gout and hyperuricemia. Probenecid is sometimes used to increase the concentration of some antibiotics and to protect the kidneys when given with cidofovir. Specifically, a small amount of evidence supports the use of intravenous cefazolin once rather than three times a day when it is combined with probenecid. It has also found use as a masking agent, potentially helping athletes using performance-enhancing substances to avoid detection by drug tests.
Sources: en.wikipedia.org
==== 2001–2006: Second double, Invincibles, and leaving Highbury ==== The cup defeat prompted Wenger to make changes to his squad. He signed young England internationals Richard Wright and Francis Jeffers, midfielder Giovanni van Bronckhorst from Rangers as a partner for Vieira, and convinced defender Sol Campbell to join from local rivals Tottenham Hotspur on a free transfer. Campbell's arrival strengthened a defence which was going through a transition phase from 1999 and 2001; Steve Bould and Nigel Winterburn moved on in this period, club graduate Ashley Cole displaced Sylvinho as Wenger's first choice left back, while Lauren acted as Lee Dixon's understudy. Midfielders Freddie Ljungberg and Robert Pires – brought in during preceding transfer windows, had now established themselves into the first team. The 2001–02 season brought much success as Wenger led Arsenal to the double once more. The crowning moment was the win against Manchester United at Old Trafford in the penultimate game of the season. Sylvain Wiltord scored the winning goal to secure the club's 12th league championship and third double; four days earlier, Arsenal beat Chelsea 2–0 in the 2002 FA Cup Final. The team scored in every single league fixture and were unbeaten away from home that season.
=== Mineral resources === Ningxia is rich in mineral resources with proven deposits of 34 kinds of minerals, much of which located in grassland areas. In 2011 it was estimated that the potential value per capita of these resources accounted for 163.5 percent of the nation's average. Ningxia boasts verified coal reserves of over 30 billion tons, with an estimated reserve of more than 202 billion tons, ranking sixth nationwide. Coal deposits are spread over one-third of the total surface of Ningxia, and mined in four major fields in the Helan and Xiangshan mountains, Ningdong and Yuanzhou (or Guyuan). The region's reserves of oil and natural gas can be found in Yanchi and Lingwu County, and are ideal for large-scale development of oil, natural gas and chemical industries. Ningxia leads China in gypsum deposits, with a proven reserve of more than 4.5 billion tons, of which the rarely found, top-grade gypsum accounts for half of the total deposits. The Hejiakouzi deposit in Tongxin County features a reserve of 20 million tons of gypsum with a total thickness of 100 meters. There is a considerable deposit of quartz sandstone, of which 17 million tons have been ascertained. In addition, there are phosphorus, flint, copper, iron, barite, other minerals and Helan stone – a special clay stone.
The batch-to-batch variations arising from the needs during the mentioned methodology can be overcome by utilizing technical components for mixing and growth as well as transport and temperature adjustments. For the production of CdSe based semiconductor nanoparticles this method has been investigated and tuned to production amounts of kilograms per month. Since the use of technical components allows for easy interchange in regards of maximum throughput and size, it can be further enhanced to tens or even hundreds of kilograms. In 2011 a consortium of U.S. and Dutch companies reported a milestone in high-volume quantum dot manufacturing by applying the traditional high temperature dual injection method to a flow system. On 23 January 2013 Dow entered into an exclusive licensing agreement with UK-based Nanoco for the use of their low-temperature molecular seeding method for bulk manufacture of cadmium-free quantum dots for electronic displays, and on 24 September 2014 Dow commenced work on the production facility in South Korea capable of producing sufficient quantum dots for "millions of cadmium-free televisions and other devices, such as tablets". Mass production was due to commence in mid-2015. On 24 March 2015, Dow announced a partnership deal with LG Electronics to develop the use of cadmium free quantum dots in displays.
=== Binding with HLA-DO === HLA-DO binds to the same regions of HLA-DM as MHC class II molecules do, such that it blocks the ability of HLA-DM to bind with MHC. Thus, you can never have a complex containing HLA-DM, HLA-DO, and MHC class II molecules.
In 1987, Tengku Razaleigh Hamzah, who had been demoted from Finance Minister to Trade and Industry Minister, challenged Mahathir for UMNO's presidency, and effectively the prime ministership. Razaleigh's bid was supported by Musa, who had resigned as deputy prime minister the previous year. While once close allies with Mahathir, both fell out with Musa claiming that Mahathir no longer trusted him. Razaleigh and Musa ran for the UMNO presidency and deputy presidency on a joint ticket against Mahathir and his new choice for deputy Abdul Ghafar Baba. Mahathir's Team A enjoyed the press's support, most party heavyweights, and even Iskandar, now the Agong. However, other prominent figures such as Abdullah Ahmad Badawi supported Team B. In the election, held on 24 April 1987, Team A prevailed. Mahathir was re-elected by a narrow margin, receiving the votes of 761 party delegates to Razaleigh's 718. Ghafar defeated Musa by a slightly larger margin. Mahathir responded by purging seven Team B supporters from his ministry. At the same time, Team B refused to accept defeat and initiated litigation. In an unexpected decision in February 1988, the High Courts ruled that UMNO was an illegal organisation as some of its branches had not been lawfully registered. Each faction raced to register a new party under the UMNO name. Mahathir's side successfully registered the name "UMNO Baru" ("new UMNO"), while Team B's application to register "UMNO Malaysia" was rejected. Nevertheless, UMNO Malaysia registered the party as Semangat 46 instead under Tengku Razaleigh Hamzah's leadership.
Sources: en.wikipedia.org
Chemical degradation such as hydrolysis and oxidation proceeds more slowly as temperature falls. Cold storage also limits microbial growth in reconstituted material. Repeated warming should be avoided because thermal cycling stresses the peptide.
Retention time supports consistency but does not establish structure by itself. A different compound can elute at a similar time under one set of conditions. Mass spectrometry or comparison with a verified standard is normally required alongside the chromatographic result.
The lactam bridge constrains the peptide backbone and limits attack by some exopeptidases. It does not protect against hydrolysis of amide bonds inside the ring or against oxidative modification of susceptible residues. Stability therefore still depends heavily on storage conditions.
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.